Stifel maintains Syndax stock rating after trial failure

Syndax Pharmaceuticals (SNDX) shares fell 17.2% to $13.70 in pre-market trading after its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint. Other stocks moving lower include BioNTech (BNTX), down 6.1% to $90.01, and Seagate (STX), down 5.7% to $710.10, among others.

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

Syndax Pharmaceuticals (SNDX) reported that its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) missed the primary endpoint. The trial evaluated the drug's efficacy and safety in 145 patients across 62 sites. Despite the setback, axatilimab was well tolerated, and Syndax will continue its development for chronic graft-versus-host disease (cGVHD).

Syndax Pharmaceuticals (SNDX) reported that its Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The drug was well tolerated, and the company will not advance it for IPF but will continue trials in other indications. SNDX stock fell 2.59% on Monday and is down 16.07% in overnight trading.

Syndax Pharmaceuticals (SNDX) fell 15% in after-hours trading after its drug axatilimab failed to meet the primary endpoint in a phase 2 trial for idiopathic pulmonary fibrosis. The trial aimed to reduce the rate of decline in forced vital capacity.

Syndax Pharmaceuticals (SNDX) shares dropped 15% after its axatilimab drug failed to meet the primary endpoint in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). The trial did not show a significant decline in forced vital capacity (FVC). The company will not pursue further IPF development but continues trials for chronic graft-versus-host disease (cGVHD) and other indications.